Ajay K. Nooka, MD | Authors

The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM

September 21, 2022

An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.

Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?

September 14, 2022

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.

Comparing Combination Treatment Regimens in Transplant-Eligible NDMM

September 14, 2022

Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.